Is there a role for pembrolizumab beyond progression in urothelial carcinoma?

被引：0
|
作者：
Taguchi, Satoru [1 ]
Kawai, Taketo [2 ]
Nakagawa, Tohru [2 ]
Kume, Haruki [1 ]
机构：
[1] Univ Tokyo, Grad Sch Med, Dept Urol, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1138655, Japan
[2] Teikyo Univ, Sch Med, Dept Urol, Tokyo, Japan
来源：
BJU INTERNATIONAL | 2024年 / 134卷 / 01期
关键词：
D O I：
10.1111/bju.16245
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：43 / 44
页数：2
相关论文
共 50 条
  • [21] UROTHELIAL CARCINOMA EXOSOMES PROMOTE CANCER PROGRESSION
    Beckham, Carla
    Silvers, Christopher
    Yin, Peng-Nien
    Wu, Chia-Hao
    Ting, Huei-Ju
    Messing, Edward
    Lee, Yi Fen
    JOURNAL OF UROLOGY, 2013, 189 (04): : E462 - E462
  • [22] Immunotherapy for urothelial carcinoma: Metastatic disease and beyond
    Poon, Darren Ming-Chun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 18 - 23
  • [23] Beyond Promoter: The Role of Macrophage in Invasion and Progression of Renal Cell Carcinoma
    Zhang, Haibao
    Zhu, Guodong
    CURRENT STEM CELL RESEARCH & THERAPY, 2020, 15 (07) : 588 - 596
  • [24] Pembrolizumab-Induced Giant Cell Arteritis in the Setting of Urothelial Carcinoma
    Miano, Deanna Ingrassia
    Cosgrove, Ryan
    Sherman, Joshua
    Balaraman, Savitha
    Sherman, Michael
    NEURO-OPHTHALMOLOGY, 2023, 47 (02) : 93 - 99
  • [25] Initial experience of Pembrolizumab for metastatic urothelial carcinoma at Juntendo Hospital, Japan
    Kitamura, K.
    Muto, S.
    Ieda, T.
    Ashizawa, T.
    Noma, Y.
    China, T.
    Nagata, M.
    Isotani, S.
    Wakumoto, Y.
    Horie, S.
    INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 : 156 - 156
  • [26] The relationship between the therapeutic effect of pembrolizumab on advanced urothelial carcinoma and MDSC
    Wakita, Haruhiko
    Lu, Yan
    Nagata, Masayoshi
    Horie, Shigeo
    CANCER SCIENCE, 2023, 114 : 1182 - 1182
  • [27] Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma
    Wataru Fukuokaya
    Takafumi Yanagisawa
    Masaki Hashimoto
    Shutaro Yamamoto
    Yuhei Koike
    Yu Imai
    Kosuke Iwatani
    Hajime Onuma
    Kagenori Ito
    Fumihiko Urabe
    Shunsuke Tsuzuki
    Shoji Kimura
    Jun Miki
    Yu Oyama
    Hirokazu Abe
    Takahiro Kimura
    Cancer Immunology, Immunotherapy, 2023, 72 : 841 - 849
  • [28] Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma
    Fukuokaya, Wataru
    Yanagisawa, Takafumi
    Hashimoto, Masaki
    Yamamoto, Shutaro
    Koike, Yuhei
    Imai, Yu
    Iwatani, Kosuke
    Onuma, Hajime
    Ito, Kagenori
    Urabe, Fumihiko
    Tsuzuki, Shunsuke
    Kimura, Shoji
    Miki, Jun
    Oyama, Yu
    Abe, Hirokazu
    Kimura, Takahiro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (04) : 841 - 849
  • [29] A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).
    Hussain, Maha H. A.
    Kocherginsky, Masha
    Singh, Parminder
    Myint, Zin
    Jiang, Di Maria
    Wulff-Burchfield, Elizabeth Marie
    Sharon, Elad
    Piekarz, Richard
    Meeks, Joshua J.
    VanderWeele, David James
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [30] Hyperprogression after pembrolizumab treatment in two patients with metastatic urothelial carcinoma
    Hatano, Takashi
    Matsu-ura, Taishi
    Mori, Kei-ichiro
    Inaba, Hiroyuki
    Endo, Katsuhisa
    Tamari, Mayumi
    Egawa, Shin
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (05) : 473 - 476
12345